Clinical Trial

Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.

Study acronym: NOMEM-Tau
Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 6, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single center brain Positron Emission Tomography (PET) study of 18F-MK-6240. Eligible participants are persons from Northern Manhattan who self-identify as Hispanic, non-Hispanic Black, or Non-Hispanic White, who are 55 to 69 years of age, of both sexes, without dementia, who have already agreed to undergo, of have undergone, brain amyloid PET and magnetic resonance imaging (MRI). Those eligible will have one brain PET scan with 18F-MK-6240, repeated after 18 months to 30 months. Vital signs will be checked prior to injection of 18F-MK-6240 and again at the completion of the PET scan. The primary objective is to relate diabetes status and glycemia to in-vivo brain tau accumulation, across and within ethnic and racial groups.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-12-27; most recent amendment 2025-05-05.
Status change: Not Yet Recruiting → Enrolling by Invitation 2018-03-14
Trial Details
NCT Number NCT03389100
Lead Sponsor Columbia University
Collaborators: Hebrew Home at Riverdale, National Institute on Aging (NIA)
Conditions Diabetes Mellitus, Type 2, Pre-diabetes
Enrollment 600 participants
Start Date 2018-07-24
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-05-06